Aug 26, 2021 / NTS GMT
Osamu Okuda - Chugai Pharmaceutical Co., Ltd. - President, CEO & Representative Director
Good afternoon. I am President Okuda. Thank you very much for joining us today. First, I would like to give you an overview of Chugai's efforts to develop the therapeutic drugs for COVID-19.
This slide shows the major milestones in the development in Japan to date. First, we started to work in-house product, Actemra. Roche started the global study, COVACTA, in March 2020. Around the same time, in parallel, we started the Phase III study J-COVACTA in Japan for similar patients in May 2020. Then we acquired the rights to develop and market Ronapreve in Japan, and antibody cocktail therapy in December, and also acquired the rights for AT-527, an oral antiviral agent under the strategic alliance with Roche in February this year. Then in May, we reached an agreement with the Japanese government to secure the supply of Ronapreve for 2021.
We submitted an application for special approval on June 29th, and received the approval on July 19th, in an exceptionally short review period of 3 weeks. We were able to
Chugai Pharmaceutical Co Ltd Information Meeting on RONAPREVE Transcript
Aug 26, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers